Teva Falls Further Behind AZ, Sanofi With Phase III Subcutaneous Cinqair Failure
Teva has hit a stumbling block in its attempt to catch up with rivals and develop a subcutaneous version of its asthma therapy Cinqair with the failure of two Phase III studies.
You may also be interested in...
The company is keeping up the pressure on GSK, getting approval for self-administration for Fasenra a few months after a similar green light for severe asthma rival Nucala.
While its NDA languishes at the US Food and Drug Administration, the EMA’s CHMP has said yes to dostarlimab’s marketing in the EU for endometrial cancer.
After a baptism of fire during the coronavirus pandemic, mRNA vaccine technology has earned its stripes. In less than a year, mRNA vaccines have been catapulted from interesting pipeline prospects to game-changers in the fight against COVID-19. But what does this success mean for the future of the technology?